CAR-T r/r B-cell NHLの世界市場予測

◆英語タイトル:CAR-T r/r B-cell NHL global market forecast
◆商品コード:VACZ712009
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年8月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD5,925 ⇒換算¥651,750見積依頼/購入/質問フォーム
PDF+ExcelUSD4,145 ⇒換算¥455,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of malignancies which have a wide range of histological appearances and clinical features. They are divided into two prognostic groups: Indolent lymphomas and Aggressive lymphomas. Of the B-cell type aggressive forms, Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FL) are common types accounting for around 65% of cases (WHO figures). DLBCL is most common in people over 50 and has a current 5-year survival rate around 62%. It is estimated that approximately 26,000 people will be diagnosed with DLBCL in the United States in 2016.
There are many treatment strategies for NHLs including radiation therapy, chemotherapy (e.g. CHOP, CVP) and various combinations with rituximab or other anti-CD20 mAbs. Stem cell or bone marrow transplant is an also option for certain patients. There is a high unmet need within the relapsing/refractory subset of patients who have an extremely poor prognosis.

New treatments for NHL under investigation include the checkpoint inhibitors (PD-1 and PD-L1), therapeutic vaccines (CDX-301, SD101) and CAR-T cell therapies: Axi-Cel/KTE-C19, JCAR017 and CTL019 (tisagenlecluecel-T) developed by Kite Pharma, Juno Therapeutics and Novartis Pharmaceuticals respectively. Kite’s KTE-C19 has already been filed in the US for DLBCL with Novartis and Juno expected to follow closely in both US and the EU.

This MarketVIEW product consists of a detailed Executive presentation (~177 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in adult r/r NHL B-cell type lymphomas (new cases) across 9 major Western markets to 2030. A patient-based flow methodology has been devised where two possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of NHL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T NHL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided

【レポートの目次】

Contents
Executive summary
Author’s note
CAR-T treatment for r/r B-cell NHLs – commercial model: key outputs
CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) Global
CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) USA only
CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) M5EU only
CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) Global
CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) USA only
CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) M5EU only
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (Global)
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (USA only)
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (M5EU only)
CAR-T cell therapy: projected NHL revenue forecast per competitor ($000s) (45-74 yrs) to 2030 (Global)
CAR-T treatment for r/r B-cell NHLs – commercial model: key outputs
CAR-T eligible NHL patients/line of therapy to 2030 (all ages) Global
CAR-T eligible NHL patients/line of therapy to 2030 (all ages) USA only
CAR-T eligible NHL patients/line of therapy to 2030 (all ages) M5EU only
CAR-T treated NHL patients/line of therapy to 2030 (all ages) Global
CAR-T treated NHL patients/line of therapy to 2030 (all ages) USA only
CAR-T treated NHL patients/line of therapy to 2030 (all ages) M5EU only
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (Global)
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (USA only)
CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (M5EU only)
CAR-T cell therapy: projected NHL revenue forecast per competitor ($000s) (all ages) to 2030 (Global)
Non-Hodgkin Lymphoma (NHL): disease background and epidemiology
Non-Hodgkin lymphoma (NHL): classification
NHL: Relative frequencies of B cell lymphoma subtypes in adults
Diffuse Large B cell Lymphoma (DLBCL)
Follicular Lymphoma (FL)
NHL: World incidence and mortality rates, region and sex
NHL: overall statistics in the US
NHL: new cases and deaths in US
NHL: cases by stage
NHL: NHL incidence vs other cancer types in US 2017
NHL: US Incidence and death rate by age
NHL: US incidence by sex and race/ethnicity
NHL: US new cases and deaths 1975-2014 and five-year survival
NHL: overall statistics in the UK
NHL: UK new cases and incidence rates by country (2014)
NHL: UK new cases and incidence rate by age and sex (2012-2014)
NHL: UK incidence and mortality rate over time
NHL: UK number of deaths and mortality rate by country and sex (2014)
NHL: UK incidence by stage at diagnosis
3 Contents available on request
2 Presentation titles may apply to more than one slide

NHL: UK incidence projections to 2035
NHL: UK prevalence statistics
NHL: UK mortality projections to 2035
NHL: European incidence by sex (2012)
NHL: European mortality by sex (2012)
NHL: Prevalence in Europe, both sexes, 2012
NHL: Prevalence in Europe, by sex 2012
NHL: Canada - incidence and mortality statistics, 2012
NHL: Canada - prevalence statistics, 2012
NHL: Japan - incidence and mortality statistics, 2012
NHL: Japan - prevalence statistics, 2012
NHL: Australia - incidence and mortality statistics, 2012
NHL: Australia - prevalence statistics, 2012
NHL: Incidence and mortality comparison - US, Canada, Europe, Japan, Australia in 2012
Non-Hodgkin Lymphoma - disease classification and diagnosis
Further classification of NHL
NHL: symptoms and diagnosis
NHL: International Prognostic Index
Non-Hodgkin Lymphoma – treatment
NHL: Treatment (Adults)
NHL: Treatment for relapsed disease (Adults)
NHL: Treatment (Adults)
NHL: Treatment for relapsed disease (childhood)
Immunotherapy for NHL
Checkpoint inhibitors
Monoclonal antibodies
Therapeutic vaccines
Adoptive T-cell therapies
NHL: The unmet need for DLBCL
SCHOLAR-1 DLBCL outcomes study
Novel treatments for NHL: CAR-T cell therapy
Chimeric Antigen Receptor T cells (CAR-T): overview
Chimeric Antigen Receptor T cells (CAR-T): second generation
Chimeric Antigen Receptor T cells (CAR-T): antigen selection
CAR-T cell therapy: potential issues and challenges
CAR-T cell therapy for NHL: pipeline analysis methodology
CAR-T cell therapy for NHL: pipeline analysis findings
Pipeline analysis table: industry sponsored CAR-T studies for NHL
Kite Pharma: Axi-Cel (KTE-C19)
Kite Pharma: CAR R&D pipeline, July 2017
Axi-Cel (KTE-C19): ZUMA-1 study design
Axi-Cel (KTE-C19): ZUMA-1 - Phase I data
Axi-Cel (KTE-C19): ZUMA-1 - pivotal Phase 2 data
Axi-Cel (KTE-C19): ZUMA-1 - summary of data
Axi-Cel (KTE-C19): National Cancer Institute (NCI) studies
Axi-Cel (KTE-C19): durable complete remission in aggressive NHL
Axi-Cel (KTE-C19) in combination with checkpoint inhibitor atezolizumab
Axi-Cel (KTE-C19): manufacturing process
Axi-Cel (KTE-C19): the path to commercialization
Axi-Cel (KTE-C19): Joint ventures and infrastructure building
Juno Therapeutics Inc, Celgene Corporation: JCAR017
Juno Therapeutics Inc - CAR and TCR R&D pipeline
Juno/JCAR017: Lead candidate
Juno/JCAR017: Phase I (TRANSCEND) design
Juno/JCAR017: Phase I (TRANSCEND) data
Juno/JCAR017: Summary
Other NHL Juno data
Juno/JCAR014: Phase I/II design
Juno/ JCAR014: Phase I - published data
Juno/JCAR014: further Phase I/II data
Juno/ MedImmune LLC: JCAR014 - combination study
Juno/MedImmune LLC: JCAR018 - Phase I design

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CAR-T r/r B-cell NHLの世界市場予測(CAR-T r/r B-cell NHL global market forecast)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆